title: PCV chemotherapy for oligodendroglioma: response analyzed on T2 weighted-MRI.
abstract: OBJECTIVE
  Because oligodendroglioma are infiltrative tumors, the Mac Donald's response criteria, usually used for solid and contrast-enhanced tumors, seem not to be adapted. To precise more relevant radiological criteria, the radiological response of oligodendroglioma to PCV chemotherapy was evaluated on T2 weighted-MRI sequences only.
  
  
  METHODS
  25 patients with oligodendroglioma grade A or B were retrospectively analyzed. They were treated with up to six cycles of PCV standard regimen. Tumor size was calculated before and at the end of the treatment, on T2 weighted-MRI, by two methods: volumetric reconstruction (method 1) and maximal cross-sectional area (method 2). Responses were defined according to new criteria on T2 weighted-MRI.
  
  
  RESULTS
  According to these criteria and with the method 1, 7 of 25 patients (28%) had a partial response to the PCV, 14 patients (56%) had stabilized disease, and 4 patients (16%) had progressive disease. With the method 2, 6 had partial response (24%), 18 had stabilized disease (72%) and 1 had progressive disease.
  
  
  CONCLUSIONS
  Response rate to PCV chemotherapy in this study was lower than response observed in the literature. Because of the infiltrative feature of oligodendroglioma, we think that the radiological response of these tumors should be evaluated on T2 weighted-MRI. The two methods of tumor size estimation used in this study were almost equivalent. Then, the maximal cross-sectional area measurement, more practical, could be retained.
authors.affiliation: Department of Neurosurgery, University Hospital of Angers, France.
authors.forename: S
authors.initials: S
authors.lastname: Diabira
authors.forename: M C
authors.initials: MC
authors.lastname: Rousselet
authors.forename: E
authors.initials: E
authors.lastname: Gamelin
authors.forename: P
authors.initials: P
authors.lastname: Soulier
authors.forename: E
authors.initials: E
authors.lastname: Jadaud
authors.forename: P
authors.initials: P
authors.lastname: Menei
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008130:Lomustine / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009837:Oligodendroglioma / Q000175:diagnosis / Q000188:drug therapy*; D011344:Procarbazine / Q000627:therapeutic use*; D011379:Prognosis; D011878:Radiotherapy; D012189:Retrospective Studies; D014750:Vincristine / Q000627:therapeutic use*
chemical_list: D011344:Procarbazine; D014750:Vincristine; D008130:Lomustine